EN DE
STOCK COMPARISON

Shanghai Henlius Biotech vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Shanghai Henlius Biotech (2696) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Shanghai Henlius Biotech trades at HK$70.10 versus a fair value of HK$31.51 (-55%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).
Shanghai Henlius Biotech
2696.HK · HKD · Health Care
-55%
upside to fair value
overvalued
PriceHK$70.10
Fair ValueHK$31.51
Quality58/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-50%
upside to fair value
overvalued
Price$558
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Shanghai Henlius BiotechVertex Pharmaceuticals
Valuation
39.6×P/E (TTM)28.8×
5.64×P/S (TTM)10.06×
9.48×P/B6.59×
32.8×EV/EBITDA23.8×
—PEG1.72×
−55.0%Fair value upside−50.0%
—Dividend yield0.1%
Profitability
10%Operating margin38%
—EBIT margin trend (5Y)0.86×
24%Return on equity24%
4%Return on assets12%
Growth
29%Revenue growth (YoY)8%
27.5%Avg. growth/yr (3Y)10.6%
62.5%Avg. growth/yr (5Y)14.2%
+13.7%Value creation/yr+13.6%
Balance & size
8.2×Interest coverage (EBIT/interest)357.9×
0.34×Debt / equity0.03×
$5BMarket cap$123B
mixedGrowth qualityhealthy

Vertex Pharmaceuticals leads: 4 to 9 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Shanghai Henlius Biotechof which business quality 58 · market factors 41 Vertex Pharmaceuticalsof which business quality 77 · market factors 79
ProfitabilityMargins and returns on capital today
57
72
Quality GrowthAre margins and returns improving?
50
65
CashflowEarnings quality: real cash, not paper profit
63
79
Fin. StrengthBalance sheet, leverage, solvency risk
53
92
InvestmentDisciplined investing over empire-building
43
58
Low VolatilityCalm price path (market factor)
50
85
MomentumPrice trend over the last 3–12 months (market factor)
40
70
52W MomentumDistance to the 52-week high (market factor)
31
89
Net IssuanceBuybacks instead of dilution
78
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyShanghai Henlius BiotechPrice HK$70.10Vertex PharmaceuticalsPrice $558
DCF Models-29%below the priceHK$49.95-19%below the price$453
Earnings-Based-26%below the priceHK$51.65-8%close to the price$516
Dividend Discountn/a-99%below the price$7.07
Multiples-64%below the priceHK$25.09-50%below the price$278
Asset-Based-93%below the priceHK$4.86-91%below the price$49.27
Growth DCF-41%below the priceHK$41.33-38%below the price$348
Economic Profit-73%below the priceHK$18.93-54%below the price$254
Growth Earnings-2%close to the priceHK$68.56+24%above the price$692
Minimum-93%below the priceHK$4.86-99%below the price$7.07
Maximum-2%close to the priceHK$68.56+24%above the price$692
Median-41%below the priceHK$41.33-44%below the price$313
Geometric mean-59%below the priceHK$28.91-67%below the price$185

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Shanghai Henlius Biotech: 24 of 24 models see the stock below the current price.

Vertex Pharmaceuticals: 22 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Shanghai Henlius Biotech
Bear HK$21.88Fair Value HK$31.51Bull HK$40.40
HK$70.10 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$558 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Shanghai Henlius Biotech · Health Care

Quality score58 · above median
Fair value upside-55% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Shanghai Henlius Biotech trades at HK$70.10 versus a fair value of HK$31.51 (-55%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Shanghai Henlius Biotech · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Shanghai Henlius Biotech

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Vertex Pharmaceuticals

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.